Loading...
Please wait, while we are loading the content...
Similar Documents
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?
| Content Provider | Europe PMC |
|---|---|
| Author | Gallwitz, Baptist |
| Copyright Year | 2014 |
| Abstract | Abstract Safe and effective therapies for type 2 diabetes are needed to reduce the burden of late complications and costs associated with this chronic disease. Hypoglycaemia and body weight gain are side effects and limitations of the therapy with insulin and/or sulphonylureas. Recently, the combination of glucagon-like peptide-1 (GLP-1) receptor agonists and insulin has become available, which is associated with good efficacy and less risk for hypoglycaemia and weight gain. This editorial discusses the strategies to escalate treatment in type 2 diabetes in view of this novel combination and discusses its placement within the therapeutic algorithm of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Recent developments to simplify this combination therapy are also dealt with. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5983089&blobtype=pdf |
| Page Count | 2 |
| ISSN | 17583772 |
| Volume Number | 10 |
| PubMed Central reference number | PMC5983089 |
| Issue Number | 2 |
| PubMed reference number | 29872471 |
| Journal | European Endocrinology [Eur Endocrinol] |
| e-ISSN | 17583780 |
| DOI | 10.17925/ee.2014.10.02.98 |
| Language | English |
| Publisher | Touch Medical Media |
| Publisher Date | 2014-08-28 |
| Access Restriction | Open |
| Rights License | © Touch Medical Media 2014 |
| Subject Keyword | Type 2 diabetes glucagon-like peptide-1 incretins combination therapy insulin therapy exenatide liraglutide lixisenatide |
| Content Type | Text |
| Resource Type | Article |
| Subject | Endocrine and Autonomic Systems Endocrinology, Diabetes and Metabolism Endocrinology |
